French multinational pharmaceutical company Sanofi has enlisted Thread as a global decentrialised clinical trial provider under a five-year collaboration deal.

Thread is a technology and consulting service provider of electronic clinical outcome assessments (eCOA) and decentralised clinical trials (DCTs).

Under this collaboration, Thread will act as the exclusive provider of unified DCTs and eCOA technology for the pharma company’s Integrated Patient Platform (IPP), which forms a part of its global Act4Patients programme.

Thread will support Sanofi’s plan of reimagining its clinical research programme around technology and enhancing diversity, inclusion, and accessibility for patients.

Its technology and services enable patient-centric, flexible, and inclusive clinical trials, and thereby offers an interconnected and uniform digital experience for patients, investigators, and sites across their clinical trials programme.

By tapping Thread’s platform, Sanofi will be able to carry out studies globally, as well as customise trial design in line with research participant and site requirements.

The pharma company commissioned its ACT4Patients programme to reshape clinical studies and allow wider patient access to clinical research via technology and new research approaches.

Under the integrated patient platform, Sanofi selected Thread as its only collaborator to help boost digital transformation and speed up the clinical development timeline.

Sanofi senior vice-president for global head of clinical sciences and operations Lionel Bascles said: “At Sanofi, patients are at the heart of everything we do, and that includes helping them to participate in clinical trials. We are excited to partner with Thread as we pursue our vision of transforming clinical research through the lens of the patient.

“This collaboration will enhance our efforts to connect and engage patients and investigators as we continue on our mission to decentralise clinical trials and extend these life-changing opportunities to more patients across the world.”

Thread CEO John Reites said: “Thread’s technology platform is transforming clinical research through its ability to increase efficiencies, improve patient engagement, and most importantly, enable patients who previously did not have access to studies to participate in them.

“We are honoured that Sanofi selected Thread to support its bold and industry-leading commitment to put patients at the centre of all their studies through its ACT4Patients Programme.”

Decentralised Clinical Trial coverage in Clinical Trials Arena is supported by Huma.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.